IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Reck, M., Kowanetz, M., Socinski, M. A., Zou, W., McCleland, M., Yang, N., Chavez, Lopez A., Spira, A., Mazieres, J., Braiteh, F., Shames, D., Sandler, A.

funding text

  • Martin Reck: Financing of Scientific Research: Eli Lilly, F. Hoffmann-La Roche, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Merck, Novartis, Pfizer, Celgene. Alan Sandler: Financing of Scientific Research: Genentech, Roche.

authors

Publication Date

  • January 1, 2018

webpage

published in

category

start page

  • 239

end page

  • 239

volume

  • 41

WoS Citations

  • 0

WoS References

  • 0